ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ALBO Albireo Pharma Inc

44.15
0.00 (0.00%)
Mar 27 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 44.10
Ask Price 44.33
News -
Company Name Stock Ticker Symbol Market Type
Albireo Pharma Inc ALBO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 44.15 20:00:00
Open Price Low Price High Price Close Price Prev Close
44.15 44.15
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 44.15 USD

Albireo Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 913.96M - - - -2,420.78
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Albireo Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ALBO Message Board. Create One! See More Posts on ALBO Message Board See More Message Board Posts

Historical ALBO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years34.7345.2316.0229.43288,8369.4227.12%
5 Years32.0652.9011.2630.39215,23712.0937.71%

Albireo Pharma Description

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Your Recent History

Delayed Upgrade Clock